Pretreatment evaluations included a medical history, physical and neurological examination, and assessment for study eligibility based on predefined inclusion/exclusion criteria. Radiographic assessments included 6-view x-rays and magnetic resonance imaging of the lumbar spine. All TDR implants were placed via an anterior retroperitoneal approach. Patients returned for follow-up visits at 6 weeks, 3 months, 6 months, and annually thereafter. A physical examination, neurological assessment, and 6-view x-rays were performed at all follow-up visits.
The primary endpoint of this study was a composite treatment success outcome at the 2-year follow-up visit. Treatment success required patients to meet all of the following criteria: a) ≥15 point improvement in Oswestry Disability Index (ODI), b) maintenance or improvement in neurological status, c) maintenance or improvement in range of motion at the index level, d) freedom from revision, reoperation, removal, or supplemental fixation at the index level, and e) freedom from serious device-related adverse events (AEs). Secondary outcomes included back pain severity, ODI, health-related quality of life assessed with the SF-36 questionnaire, patient satisfaction, return to work, range of motion at the index level, radiographic evaluations of device status, AEs, and reoperations. A serious AE was defined as any event that was fatal, was life-threatening, required prolonged hospitalization, resulted in permanent anatomic or physiological impairment, caused a malignant tumor, or resulted in distress, congenital anomaly, or death of a fetus. Serious device-related AEs were those specifically caused by the TDR.
The primary hypothesis was that the composite treatment success outcome at 2 years in patients treated with the activL disc would be noninferior to controls. A noninferiority margin of 15% was specified in the protocol. The FDA subsequently requested to also use a 10% noninferiority margin. A test for superiority was specified a priori if noninferiority was met.10
Sample size was estimated using an O’Brien–Fleming group sequential spending function. Assumptions included a 65% success rate in each group, one-sided alpha = 0.05, power = 80%, 15% noninferiority margin, 2:1 allocation ratio, 10% loss to follow-up, and an interim analysis when at least 70% of patients in each group completed 2-year follow-up. A sample size of 194 activL patients and 97 controls was calculated using EAST version 5 (Aptiv Solutions, Reston, VA).
Patients were randomly allocated to implant with activL or control artificial discs using a 2:1 permuted block randomization scheme at each site. In patients randomized to the activL group, a spike or keel endplate was selected based on surgeon's preference. In patients allocated to the control group, choice of TDR (ProDisc-L or Charité) was also based on surgeon's preference. In general, ProDisc-L users selected the activL keel design and Charité users selected the activL spike design due to comparable endplate fixation characteristics.
Patients were blinded to treatment assignment through 2 years post-treatment. The Clinical Events Committee (CEC) was blinded to treatment assignment and patient outcomes to the extent possible. Investigators were aware of treatment assignment. All statistical analyses were performed in a blinded fashion.
Data were monitored by an independent contract research organization. A CEC reviewed AEs and secondary surgical interventions to ensure consistency in reporting, and adjudicated all AEs. An imaging core laboratory independently reviewed radiographic endpoints.
Continuous data were reported as mean ± standard deviation and categorical data were reported as frequencies and percentages. Comparisons of baseline characteristics were performed with independent samples t-test, Wilcoxon signed rank test, or Fisher's exact test, as appropriate. Main outcomes were reported using an intent-to-treat population (ITT), which included all randomized patients regardless of actual treatment. Superiority assessments of the primary endpoint utilized an O’Brien–Fleming sequential spending function, which included an interim analysis tested at P < 0.019 and, if noninferiority was not established at the interim analysis, a final analysis including complete 2-year follow-up, tested at P < 0.044. Sensitivity analyses were performed for the primary endpoint in order to assess the impact of missing data under a variety of plausible assumptions.
Participant Flow and Accountability
A total of 324 patients (218 activL, 106 control) were randomized at 14 sites between January 2007 and December 2009 (figure in Supplemental Digital Content 1 http://links.lww.com/BRS/B46). Through the 2-year follow-up period, follow-up compliance was 83% with activL and 80% with control.
Baseline patient characteristics, including demographics, medical history, symptom severity, radiographic data, and neurological status were comparable between groups (Table 1). Mean age was 39 years and patients typically presented with severe back pain, moderate/severe back-specific disability, and decreased disc height.
A TDR was successfully placed in 100% of patients assigned to activL. One patient in this group erroneously received a control device; data from this patient were included in the activL group in accordance with ITT. Of the 106 controls, 64 received the ProDisc-L, 41 received the Charité artificial disc, and 1 patient did not receive a TDR due to an intraoperative posteroinferior rim fracture. A TDR was placed at L5-S1 in 70% of the patients and at L4-L5 in 30% of the patients. Operative time, procedural blood loss, and hospital stay were comparable between the groups (Table 2).
Primary Endpoint: Composite Treatment Success Outcome
The overall treatment success rate at 2 years with activL was noninferior to controls using margins of 10% and 15% (both P < 0.001). Following establishment of noninferiority, the composite primary endpoint was tested for superiority, demonstrating a higher treatment success rate with activL versus controls (P = 0.02). A number of sensitivity analyses were performed that corroborated the findings of the primary analysis. Overall, the treatment success rate with activL remained superior to that with controls under all plausible scenarios (Figure 3). Components of the primary endpoint are presented in Table 3. Patients treated with the activL disc had higher rates of radiographic success (59% vs. 43%; P < 0.01) and ODI success (75% vs. 66%; P = 0.08) compared with controls.
Secondary Effectiveness Outcomes
Most secondary outcomes at 2 years favored the activL group, although statistical significance between groups was not achieved. Over the 2-year follow-up period, back pain severity improved 74% (79 ± 15 to 21 ± 25) with activL and 68% (79 ± 15 to 26 ± 30) with controls, on average ( Figure 4). Similarly, ODI improved 67% (57 ± 14 to 19 ± 18) with activL and 61% (59 ± 14 to 24 ± 20) with controls through 2 years (Figure 5). Health-related quality of life similarly improved over 2 years between the groups (Figure 6). The percentage of patients reporting improvement in back pain severity ≥20 mm (90% vs. 83%), ODI ≥15 points (88% vs. 81%), and Physical Component Summary score ≥15% (88% vs. 81%) all favored the activL group. Patient satisfaction with treatment was over 90% in each group at 2 years (Table 4). The percentage of patients working full-time with no restrictions increased from 33% at pretreatment to 57% at 2 years with activL and from 33% to 49% with control (P = 0.39). Return to work was 1 month sooner (P = 0.08) with activL (68 days) compared with controls (97 days). Of patients who were not participating in recreational activities before TDR treatment, the percentage of those reporting regular participation at 2 years was 54% with activL and 39% with control (P = 0.02). The percentage of patients who regularly consumed narcotic medications decreased in each group over the 2-year follow-up period (activL: 65% to 31%, control: 61% to 33%; P = 0.68).
Two cases of subsidence and 1 case of device migration were identified through 2 years, all in the control group. Device disassembly was noted in 1 (0.5%) activL patient and 2 (2.3%) controls. Heterotopic ossification interfering with range of motion was identified in 1.6% and 1.1% of patients treated with activL and control, respectively. In each group, mean disc height increased from 8 ± 2 mm at baseline to 14 ± 2 mm at 2 years. The percentage of patients with disc height increase >3 mm was 94% with activL and 87% with controls (P = 0.09). Mean range of motion at the index level increased in all radiographic views with activL compared with baseline. Change in range of motion in lateral flexion–extension radiographs was statistically greater with activL compared with controls in segmental rotation (+0.9° vs. −1.4°; P < 0.01) and translation (+0.6 mm vs. +0.2 mm; P < 0.001) but not in lateral rotation on side-bending radiographs (+0.6° vs. +0.8°; P = 0.52).
Serious AEs, regardless of cause, were less common in patients treated with activL versus controls through 2 years (30% vs. 43%; P = 0.02). Serious AEs related to the TDR were also less common with activL (12% vs. 19%; P = 0.13). The most commonly reported device-related serious AEs were lumbar/leg pain (6.9% vs. 15.1%) and implant subsidence (1.4% vs. 1.9%) (Table 5). The percentage of patients undergoing surgical reintervention at the index level was comparable between groups through 2 years (activL 2.3, control 1.9; P = 1.0). The reasons for reintervention were ongoing pain (4), device malposition (2), and lumbar spinal stenosis (1).
The results of this randomized controlled trial demonstrate that the activL Artificial Disc provides clinically meaningful reductions in back pain and improvements in back-specific disability and health-related quality of life through 2 years. The primary composite treatment success endpoint with activL was statistically superior compared with FDA-approved TDRs.
The control TDRs utilized in this study previously demonstrated favorable clinical outcomes versus single-level fusion surgery in FDA-IDE randomized controlled trials. Zigler and colleagues7 evaluated the safety and effectiveness of the ProDisc-L TDR versus circumferential fusion for single-level discogenic low back pain. Patients treated with the ProDisc-L TDR reported higher rates of ODI success, neurologic success, and patient satisfaction at 2 years. The FDA-IDE trial of the Charité TDR5,6 randomized patients with single-level lumbar DDD to TDR or anterior lumbar interbody fusion. Patients treated with the Charité TDR had shorter hospitalization and reported lower levels of disability, lower reoperation rates, and higher rates of satisfaction at 2 years. These two FDA -IDE studies demonstrated that TDRs are effective treatments for single-level lumbar DDD in well-selected patients who have failed nonoperative treatment.
A recent meta-analysis of randomized controlled trials reported that TDR improved physical function, reduced pain, and shortened hospital stay in relation to fusion, although no differences were noted for operating time, procedural blood loss, and long-term complication rates.11 Additionally, the cost-effectiveness of TDR is reported to be at least comparable, if not superior, compared with fusion.12 Data from the current investigation suggest that the effectiveness and safety of activL is superior to that of the control TDRs. Given the superiority of control TDRs versus fusion in historical studies and the favorable outcomes of activL versus control TDRs in the current study, it appears plausible that activL offers advantages in comparison to fusion surgery.
The design attributes of the activL disc may account for the improved patient outcomes compared with control TDRs. The primary design advancements of the activL TDR compared with control TDRs relate to device insertion technique and range of motion. Both control TDRs are designed so that the endplates are inserted and secured without the core. After endplate placement, the disc space is distracted to allow the core to be seated in the inferior endplate. By comparison, the activL disc is implanted as a single unit (inferior and superior endplates and PE inlay) and therefore does not require this second distraction step. Additionally, the ultrahigh molecular weight PE inlay permits limited translation of the inlay, which improves range of motion, mimics the native nucleus, and may protect the facets. This device attribute likely contributed to the superior ROM outcomes with activL versus control TDRs. The influence of specific device- and procedure-related differences on patient outcomes deserves further study.
This study had several limitations. First, the long-term durability of the activL TDR is unknown and requires further investigation. Recent studies with the ProDisc-L4,13 and Charité14 TDR devices have reported excellent patient outcomes through 5 years. Second, a TDR should only be used in patients with confirmed lumbar DDD refractory to nonsurgical treatment. Third, although patients, the CEC, and statisticians were blinded to treatment allocation and imaging was independently reviewed by a core laboratory, surgeons and clinical outcome assessors were not blinded, which may influence study results. Finally, this study was underpowered to evaluate activL in comparison to each control device separately. This limitation is partially mitigated by the fact that patient characteristics and main outcomes with the ProDisc-L and Charité devices were comparable (Table, Supplemental Digital Content 2 http://links.lww.com/BRS/B46). The strengths of this study included a randomized design, rigorous study entry criteria, and use of validated outcome measures.
The activL TDR is safe and effective for the treatment of symptomatic lumbar DDD through 2 years with superior performance compared with FDA-approved TDRs.
- A total of 324 patients with single-level lumbar degenerative disc disease unresponsive to at least 6 months of nonsurgical management were randomized to treatment with the activL (n = 218) or control (n = 106) total disc replacement.
- The primary composite treatment success endpoint was statistically superior with the activL implant versus controls at 2 years (P = 0.02).
- Radiographic success, defined as maintenance or improvement in range of motion at 2 years, was significantly higher in activL (59%) versus controls (43%).
- Device-related serious adverse events were less common in patients treated with activL versus controls (12% vs. 19%).
1. Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low back pain
. Arthritis Rheum
2. Nachemson AL. Newest knowledge of low back pain
. A critical look. Clin Orthop
3. Yoshihara H, Yoneoka D. National trends in the surgical treatment for lumbar degenerative disc disease
: US, 2000–2009. Spine
4. Zigler JE, Delamarter RB. Five-year results of the prospective, randomized, multicenter, Food and Drug Administration investigational device exemption study of the ProDisc-L total disc replacement
versus circumferential arthrodesis for the treatment of single-level degenerative disc disease
, Journal of neurosurgery. Spine
5. Blumenthal S, McAfee PC, Guyer RD, et al. A prospective, randomized, multicenter Food and Drug Administration investigational device exemptions study of lumbar total disc replacement
with the CHARITE artificial disc
versus lumbar fusion: part I: evaluation of clinical outcomes. Spine
6. McAfee PC, Cunningham B, Holsapple G, et al. A prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of lumbar total disc replacement
with the CHARITE artificial disc
versus lumbar fusion: part II: evaluation of radiographic outcomes and correlation of surgical technique accuracy with clinical outcomes. Spine
7. Zigler J, Delamarter R, Spivak JM, et al. Results of the prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of the ProDisc-L total disc replacement
versus circumferential fusion for the treatment of 1-level degenerative disc disease
8. Guyer RD, Pettine K, Roh JS, et al. Comparison of 2 lumbar total disc replacements: results of a prospective, randomized, controlled, multicenter Food and Drug Administration trial with 24-month follow-up. Spine
9. Jacobs WC, van der Gaag NA, Kruyt MC, et al. Total disc replacement
for chronic discogenic low back pain
: a Cochrane review. Spine
10. Morikawa T, Yoshida M. A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. J Biopharmaceut Stat
11. Rao MJ, Cao SS. Artificial total disc replacement
versus fusion for lumbar degenerative disc disease
: a meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg
12. Guyer RD, Tromanhauser SG, Regan JJ. An economic model of one-level lumbar arthroplasty versus fusion. Spine
13. Zigler JE, Glenn J, Delamarter RB. Five-year adjacent-level degenerative changes in patients with single-level disease treated using lumbar total disc replacement
with ProDisc-L versus circumferential fusion. J Neurosurg
14. Guyer RD, McAfee PC, Banco RJ, et al. Prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of lumbar total disc replacement
with the CHARITE artificial disc
versus lumbar fusion: five-year follow-up. Spine
activL; artificial disc; back pain; degenerative disc disease; motion preservation; randomized controlled trial; total disc replacement
Supplemental Digital Content
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.